Cure Hepatitis C Act of 2025
Summary
What This Bill Does
The bill defines definitions section establishing key terms for the Hepatitis C elimination program, including hepatitis C treatment (direct-acting antivirals), correctional facility, Indian health program, and expansive, establishes the Hepatitis C Elimination Program within HHS, requiring a national strategy within 180 days, coordination across federal agencies, prioritization of high-risk populations, gap analysis, and annual, and creates a subscription-model drug purchasing program where HHS negotiates bulk purchase agreements with pharmaceutical manufacturers for hepatitis C treatments at discounted rates, distributed through registered. It relies on compliance mandates, definition changes, reporting requirements, and procurement rules. The main policy areas are Healthcare, Criminal Justice, Social Welfare, and Finance.
Who Benefits and How
Uninsured and underinsured hepatitis C patients could see lower costs, State and local public health departments could gain revenue opportunities, and Indian Health Service patients could see lower costs.
Who Bears the Burden and How
Undocumented immigrants with hepatitis C could face higher barriers, Federal Treasury could face higher costs, and Department of Health and Human Services would take on compliance duties.
Key Provisions
- Defines definitions section establishing key terms for the Hepatitis C elimination program, including hepatitis C treatment (direct-acting antivirals), correctional facility, Indian health program, and expansive...
- Establishes the Hepatitis C Elimination Program within HHS, requiring a national strategy within 180 days, coordination across federal agencies, prioritization of high-risk populations, gap analysis, and annual...
- Creates a subscription-model drug purchasing program where HHS negotiates bulk purchase agreements with pharmaceutical manufacturers for hepatitis C treatments at discounted rates, distributed through registered...
- Authorizes grants and cooperative agreements to states for hepatitis C screening, diagnosis, treatment, wraparound services, outreach, harm reduction programs including syringe services, and public health workforce...
- Provides appropriates 4.283 billion dollars in mandatory spending for the Hepatitis C Elimination Program and public health activities for FY2025 through FY2031, with a 5 percent administrative cap and 25 million dollar...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill defines definitions section establishing key terms for the Hepatitis C elimination program, including hepatitis C treatment (direct-acting antivirals), correctional facility, Indian health program, and expansive, establishes the Hepatitis C Elimination Program within HHS, requiring a national strategy within 180 days, coordination across federal agencies, prioritization of high-risk populations, gap analysis, and annual, and creates a subscription-model drug purchasing program where HHS negotiates bulk purchase agreements with pharmaceutical manufacturers for hepatitis C treatments at discounted rates, distributed through registered.
Key Policy Areas
Healthcare, Criminal Justice, Social Welfare, Finance
Primary Purpose
The bill defines definitions section establishing key terms for the Hepatitis C elimination program, including hepatitis C treatment (direct-acting antivirals), correctional facility, Indian health program, and expansive, establishes the Hepatitis C Elimination Program within HHS, requiring a national strategy within 180 days, coordination across federal agencies, prioritization of high-risk populations, gap analysis, and annual, and creates a subscription-model drug purchasing program where HHS negotiates bulk purchase agreements with pharmaceutical manufacturers for hepatitis C treatments at discounted rates, distributed through registered.
Policy Domains
Section 2 - Definitions
Identified Gains
- Uninsured and underinsured hepatitis C patients
- State and local public health departments
- Indian Health Service patients
- Incarcerated individuals with hepatitis C
- Department of Health and Human Services
Identified Costs
- Undocumented immigrants with hepatitis C
- Federal Treasury
- Department of Health and Human Services
- Syringe services programs and harm reduction organizations
Sponsors
Legislative Progress
In CommitteeMr. Cassidy (for himself and Mr. Van Hollen) introduced the …
Read twice and referred to the Committee on Health, Education, …
Introduced in Senate
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Community health centers and harm reduction organizations, Hepatitis C patients in US states and territories, Hepatitis C patients in high-risk populations
Positive-direction: Community health centers and harm reduction organizations, Hepatitis C patients in US states and territories, Hepatitis C patients in high-risk populations, Indian Health Service patients, Public health workforce, Registered pharmacies and dispensing sites, US citizens and qualifying immigrants with hepatitis C, Uninsured and underinsured hepatitis C patients
Negative-direction: Syringe services programs and harm reduction organizations
Department of Health and Human Services, Federal Bureau of Prisons, Federal Treasury
Department of Health and Human Services faces effects in multiple directions
Positive-direction: Federal Bureau of Prisons, State and local correctional systems, State and local public health departments, State public health departments
Negative-direction: Federal Treasury
At-risk populations (people who inject drugs, homeless individuals)
Pharmaceutical manufacturers of direct-acting antivirals
Undocumented immigrants with hepatitis C
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → Secretary of Health and Human Services
- "the_secretary"
- → Secretary of Health and Human Services
- "the_secretary"
- → Secretary of Health and Human Services
- "the_secretary"
- → Secretary of Health and Human Services
- "the_secretary"
- → Secretary of Health and Human Services
- "the_secretary"
- → Secretary of Health and Human Services
- "the_secretary"
- → Secretary of Health and Human Services
Key Definitions
Terms defined in this bill
A direct acting antiviral drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act for the treatment of hepatitis C virus infection
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology